CCNE1 is a potential target of Metformin for tumor suppression of ovarian high-grade serous carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7–30.
   PubMed Web of Science ®Google Scholar
• Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol. 2017;41:3–14.
   PubMed Web of Science ®Google Scholar
• Franier B, Thompson M. Early stage detection and screening of ovarian cancer: a research opportunity and significant challenge for biosensor technology. Biosens Bioelectron. 2019;135:71–81.
   PubMed Web of Science ®Google Scholar
• Norouzi-Barough L, Sarookhani MR, Sharifi M, et al. Molecular mechanisms of drug resistance in ovarian cancer. J Cell Physiol. 2018;233:4546–4562.
   PubMed Web of Science ®Google Scholar
• Lisio MA, Fu L, Goyeneche A, et al. High-Grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints. Int J Mol Sci. 2019;20. DOI:10.3390/ijms20040952
   PubMed Web of Science ®Google Scholar
• Baldwin LA, Huang B, Miller RW, et al. Ten-Year relative survival for epithelial ovarian cancer. Obstet Gynecol. 2012;120:612–618.
   PubMed Web of Science ®Google Scholar
• Lheureux S, Gourley C, Vergote I, et al. Epithelial ovarian cancer. Lancet. 2019;393:1240–1253.
   PubMed Web of Science ®Google Scholar
• Hennessy BT, Coleman RL, Markman M. Ovarian cancer. Lancet. 2009;374:1371–1382.
   PubMed Web of Science ®Google Scholar
• Boussios S, Karihtala P, Moschetta M, et al. Veliparib in ovarian cancer: A new synthetically lethal therapeutic approach. Invest New Drugs. 2020;38:181–193.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Buse JB, Davidson MB, et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2009;32:193–203.
   PubMed Web of Science ®Google Scholar
• Rodbard HW, Jellinger PS, Comment on: Inzucchi. et al. Management of hyperglycemia in type 2 diabetes: A patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364–1379. Diabetes Care. 2012;35:e70, e72-3. DOI:10.2337/dc12-0413
   PubMed Web of Science ®Google Scholar
• Morales DR, Morris AD. Metformin in cancer treatment and prevention. Annu Rev Med. 2015;66:17–29.
   PubMed Web of Science ®Google Scholar
• Wu D, Hu D, Chen H, et al. Glucose-Regulated phosphorylation of TET2 by AMPK reveals a pathway linking diabetes to cancer. Nature. 2018;559:637–641.
   PubMed Web of Science ®Google Scholar
• Patel S, Kumar L, Singh N. Metformin and epithelial ovarian cancer therapeutics. Cell Oncol (Dordr). 2015;38:365–375.
   PubMed Web of Science ®Google Scholar
• Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006;66:10269–10273.
   PubMed Web of Science ®Google Scholar
• Zhou G, Myers R, Li Y, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001;108:1167–1174.
   PubMed Web of Science ®Google Scholar
• Lee J, Yesilkanal AE, Wynne JP, et al. Effective breast cancer combination therapy targeting BACH1 and mitochondrial metabolism. Nature. 2019;568:254–258.
   PubMed Web of Science ®Google Scholar
• Al HM, Fakhoury I, El MZ, et al. Metformin treatment inhibits motility and invasion of glioblastoma cancer cells. Anal Cell Pathol (Amst). 2018;2018:5917470.
   PubMedGoogle Scholar
• Ma L, Wei J, Wan J, et al. Low glucose and metformin-induced apoptosis of human ovarian cancer cells is connected to ASK1 via mitochondrial and endoplasmic reticulum stress-associated pathways. J Exp Clin Cancer Res. 2019;38:77.
   PubMed Web of Science ®Google Scholar
• Karst AM, Jones PM, Vena N, et al. Cyclin E1 deregulation occurs early in secretory cell transformation to promote formation of fallopian tube-derived high-grade serous ovarian cancers. Cancer Res. 2014;74:1141–1152.
   PubMed Web of Science ®Google Scholar
• Nakayama N, Nakayama K, Shamima Y, et al. Gene amplification CCNE1 is related to poor survival and potential therapeutic target in ovarian cancer. Cancer-Am Cancer Soc. 2010;116:2621–2634.
   PubMed Web of Science ®Google Scholar
• Etemadmoghadam D, George J, Cowin PA, et al. Amplicon-Dependent CCNE1 expression is critical for clonogenic survival after cisplatin treatment and is correlated with 20q11 gain in ovarian cancer. PLoS One. 2010;5:e15498.
   PubMed Web of Science ®Google Scholar
• Davidson B, Skrede M, Silins I, et al. Low-Molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma. Cancer-Am Cancer Soc. 2007;110:1264–1271.
   PubMed Web of Science ®Google Scholar
• Farley J, Smith LM, Darcy KM, et al. Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a gynecologic oncology group study. Cancer Res. 2003;63:1235–1241.
   PubMed Web of Science ®Google Scholar
• Etemadmoghadam D, DeFazio A, Beroukhim R, et al. Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res. 2009;15:1417–1427.
   PubMed Web of Science ®Google Scholar
• Spruck CH, Won KA, Reed SI. Deregulated cyclin E induces chromosome instability. Nature. 1999;401:297–300.
   PubMed Web of Science ®Google Scholar
• Minella AC, Swanger J, Bryant E, et al. P53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol. 2002;12:1817–1827.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Ning G, Howitt BE, et al. In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells. J Pathol. 2016;238:519–530.
   PubMed Web of Science ®Google Scholar
• Powers RK, Goodspeed A, Pielke-Lombardo H, et al. GSEA-InContext: identifying novel and common patterns in expression experiments. Bioinformatics. 2018;34:i555–64.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–615. DOI:10.1038/nature10166
   PubMed Web of Science ®Google Scholar
• Beaufort CM, Helmijr JC, Piskorz AM, et al. Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One. 2014;9:e103988.
   PubMed Web of Science ®Google Scholar
• Li B, Zhou P, Xu K, et al. Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma. Int J Biol Sci. 2020;16:74–84.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zheng Q, Li Y, et al. Metformin targets a YAP1-TEAD4 complex via AMPKα to regulate CCNE1/2 in bladder cancer cells. J Exp Clin Cancer Res. 2019;38:376.
   PubMed Web of Science ®Google Scholar
• Wu NY, Fang C, Huang HS, et al. Natural history of ovarian high-grade serous carcinoma from time effects of ovulation inhibition and progesterone clearance of p53-defective lesions. Mod Pathol. 2020;33:29–37.
   PubMed Web of Science ®Google Scholar
• Hsu CF, Huang HS, Chen PC, et al. IGF-Axis confers transformation and regeneration of fallopian tube fimbria epithelium upon ovulation. EBioMedicine. 2019;41:597–609.
   PubMed Web of Science ®Google Scholar
• Huang HS, Chu SC, Hsu CF, et al. Mutagenic, surviving and tumorigenic effects of follicular fluid in the context of p53 loss: Initiation of fimbria carcinogenesis. Carcinogenesis. 2015;36:1419–1428.
   PubMed Web of Science ®Google Scholar
• Hsu CF, Chen PC, Seenan V, et al. Ovulatory follicular fluid facilitates the full transformation process for the development of high-grade serous carcinoma. Cancers (Basel). 2021;13. DOI:10.3390/cancers13030468
   Web of Science ®Google Scholar
• Roby KF, Taylor CC, Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585–591.
   PubMed Web of Science ®Google Scholar
• Cohen PA, Jhingran A, Oaknin A, et al. Cervical cancer. Lancet. 2019;393:169–182.
   PubMed Web of Science ®Google Scholar
• Boussios S, Zarkavelis G, Seraj E, et al. Non-Epithelial ovarian cancer: elucidating uncommon gynaecological malignancies. Anticancer Res. 2016;36:5031–5042.
   PubMed Web of Science ®Google Scholar
• Coburn SB, Bray F, Sherman ME, et al. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. Int J Cancer. 2017;140:2451–2460.
   PubMed Web of Science ®Google Scholar
• Smith LH, Morris CR, Yasmeen S, et al. Ovarian cancer: Can we make the clinical diagnosis earlier? Cancer-Am Cancer Soc. 2005;104:1398–1407.
   PubMed Web of Science ®Google Scholar
• Zhang S, Dolgalev I, Zhang T, et al. Both fallopian tube and ovarian surface epithelium are cells-of-origin for high-grade serous ovarian carcinoma. Nat Commun. 2019;10:5367.
   PubMed Web of Science ®Google Scholar
• Karnezis AN, Cho KR, Gilks CB, et al. The disparate origins of ovarian cancers: pathogenesis and prevention strategies. Nat Rev Cancer. 2017;17:65–74.
   PubMed Web of Science ®Google Scholar
• Bachert SE, McDowell AJ, Piecoro D, et al. Serous tubal intraepithelial carcinoma: a concise review for the practicing pathologist and clinician. Diagnostics (Basel). 2020;10. DOI:10.3390/diagnostics10020102
   PubMedGoogle Scholar
• Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Pathol. 2007;31:161–169.
   PubMed Web of Science ®Google Scholar
• McDaniel AS, Stall JN, Hovelson DH, et al. Next-Generation sequencing of tubal intraepithelial carcinomas. JAMA Oncol. 2015;1:1128–1132.
   PubMed Web of Science ®Google Scholar
• Ahmed AA, Etemadmoghadam D, Temple J, et al. Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol. 2010;221:49–56.
   PubMed Web of Science ®Google Scholar
• Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26–35.
   PubMed Web of Science ®Google Scholar
• Carcangiu ML, Radice P, Manoukian S, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004;23:35–40.
   PubMed Web of Science ®Google Scholar
• Bijron JG, Seldenrijk CA, Zweemer RP, et al. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol. 2013;37:1123–1130.
   PubMed Web of Science ®Google Scholar
• Hossain M, Stillman B. Opposing roles for DNA replication initiator proteins ORC1 and CDC6 in control of Cyclin E gene transcription. Elife. 2016;5. DOI:10.7554/eLife.12785
   Web of Science ®Google Scholar
• Ciriello G, Cerami E, Sander C, et al. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2012;22:398–406.
   PubMed Web of Science ®Google Scholar
• Eckert MA, Pan S, Hernandez KM, et al. Genomics of ovarian cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube. Cancer Discov. 2016;6:1342–1351.
   PubMed Web of Science ®Google Scholar
• Au-Yeung G, Lang F, Azar WJ, et al. Selective targeting of cyclin e1-amplified high-grade serous ovarian cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res. 2017;23:1862–1874.
   PubMed Web of Science ®Google Scholar
• Coyle C, Cafferty FH, Vale C, et al. Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis. Ann Oncol. 2016;27:2184–2195.
   PubMed Web of Science ®Google Scholar
• Tseng CH. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2015;31:619–626.
   PubMed Web of Science ®Google Scholar
• Urpilainen E, Puistola U, Boussios S, et al. Metformin and ovarian cancer: the evidence. Ann Transl Med. 2020;8:1711.
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care. 2010;33:1674–1685.
   PubMed Web of Science ®Google Scholar
• Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat Rev Endocrinol. 2019;15:569–589.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, McCormick F. The RB and p53 pathways in cancer. Cancer Cell. 2002;2:103–112.
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C. P53 and RB: simple interesting correlates or tumor markers of critical predictive nature? J Clin Oncol. 2004;22:975–977.
   PubMed Web of Science ®Google Scholar